CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 165 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2015. The put-call ratio across all filers is 4.61 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2018 | $70,000 | -43.1% | 29,992 | -30.7% | 0.00% | -100.0% |
Q4 2017 | $123,000 | +324.1% | 43,253 | +325.0% | 0.00% | – |
Q3 2017 | $29,000 | -31.0% | 10,176 | -2.7% | 0.00% | – |
Q3 2016 | $42,000 | -30.0% | 10,459 | -23.1% | 0.00% | – |
Q2 2016 | $60,000 | +27.7% | 13,600 | +10.4% | 0.00% | – |
Q1 2016 | $47,000 | -67.1% | 12,323 | +34.8% | 0.00% | -100.0% |
Q4 2015 | $143,000 | +12.6% | 9,143 | -24.3% | 0.00% | 0.0% |
Q3 2015 | $127,000 | +35.1% | 12,071 | +225.5% | 0.00% | 0.0% |
Q2 2015 | $94,000 | +14.6% | 3,709 | +26.4% | 0.00% | 0.0% |
Q1 2015 | $82,000 | +67.3% | 2,935 | +8.4% | 0.00% | – |
Q4 2014 | $49,000 | +16.7% | 2,708 | -16.3% | 0.00% | – |
Q3 2014 | $42,000 | -19.2% | 3,235 | +2.4% | 0.00% | – |
Q2 2014 | $52,000 | -7.1% | 3,160 | 0.0% | 0.00% | -100.0% |
Q1 2014 | $56,000 | -30.0% | 3,160 | -3.9% | 0.00% | 0.0% |
Q4 2013 | $80,000 | -78.2% | 3,287 | -68.2% | 0.00% | -66.7% |
Q3 2013 | $367,000 | +326.7% | 10,347 | +88.5% | 0.00% | +200.0% |
Q2 2013 | $86,000 | – | 5,489 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TSP Capital Management Group, LLC | 813,273 | $3,286,000 | 1.66% |
RTW INVESTMENTS, LP | 1,243,164 | $5,022,000 | 1.52% |
Marcus Capital, LLC | 112,200 | $453,000 | 0.44% |
BOGLE INVESTMENT MANAGEMENT L P /DE/ | 996,178 | $4,024,000 | 0.29% |
Benchmark Capital Advisors | 67,000 | $271,000 | 0.20% |
SUFFOLK CAPITAL MANAGEMENT LLC | 360,299 | $1,456,000 | 0.20% |
COLUMBIA WANGER ASSET MANAGEMENT LLC | 2,907,523 | $11,746,000 | 0.15% |
Virtus ETF Advisers LLC | 59,537 | $241,000 | 0.12% |
Bellevue Group AG | 160,000 | $646,000 | 0.12% |
PDT Partners, LLC | 428,300 | $1,730,000 | 0.10% |